ABVC BioPharma, Inc. develops clinical-stage therapeutic products in ophthalmology, central nervous system disorders, and oncology/hematology. Its pipeline includes botanically derived drug candidates and the ophthalmology medical device Vitargus, with disclosed programs tied to Major Depressive Disorder, Attention Deficit Hyperactivity Disorder, Non-Small Cell Lung Cancer, and retinal surgery applications.
Recurring company news covers global licensing agreements, milestone and licensing-fee receipts, partner activity involving BioLite, BioFirst, Rgene, AiBtl BioPharma, ForSeeCon Eye Corporation, and OncoX BioPharma, and updates on clinical development, regulatory preparation, and reported financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.